recombinant human ifnλ1 (PeproTech)
Structured Review

Recombinant Human Ifnλ1, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human ifnλ1/product/PeproTech
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Bat organoids reveal antiviral responses at epithelial surfaces"
Article Title: Bat organoids reveal antiviral responses at epithelial surfaces
Journal: Nature Immunology
doi: 10.1038/s41590-025-02155-1
Figure Legend Snippet: a , Venn diagrams (generated using eulerr.co ) showing the number of significantly upregulated genes determined by bulk RNA-seq in bat nasal ORG , alv ORG , or SI ORG (n = 3 each) following treatment with universal IFNα2 (uIFNα2) or IFNλ1-like compared to mock-treated. The total number of upregulated genes per treatment are indicated. Overlapping regions represent genes commonly induced by both IFNs. b , RT-qPCR analysis of IFIT3 and ISG15 expression, normalized to EEF1A1 (2 –ΔCT ), in bat nasal ORG (n = 3) treated with uIFNα2 or IFNλ1-like for 8 h, with or without ruxolitinib (n = 3). Two-sided unpaired Student’s t-tests were used to compare mRNA levels between ruxolitinib-treated and mock-treated, interferon-stimulated nasal ORG . (ns: not significant; *** P < 0.001, **** P < 0.0001). c , Gene ontology (GO) enrichment analysis of bulk RNA-seq data, performed with clusterProfiler , revealed biological processes significantly enriched among genes upregulated in uIFNα2 vs. mock-infected bat nasal ORG , alv ORG , or SI ORG after 8 h (n = 3 each). The top 10 enriched biological processes are shown. The x axis indicates the ratio of enriched to total genes within each GO term. Dot size reflects the number of enriched genes per pathway. d , Same as in (c) but for IFNλ1-like vs. mock-treated bat nasal ORG , alv ORG , or SI ORG . e , Scatter plot showing log 2 -fold changes in gene expression from bulk RNA-seq comparing human SI ORG treated with uIFNα2 ( x axis) or IFNλ1-like ( y axis) to mock-treated controls after 8 h (n = 3). Individual ISGs and selected pro-inflammatory cytokines (red) are highlighted and labeled. f , same as in (c) but for uIFNα2 (left) or IFNλ1 (right) vs. mock-treated human SI ORG . g , Same as in (e) but for human bronchial ALI (n = 3). h , Same as in (f) but for GO enrichment analysis of uIFNα2 (left) or IFNλ1 (right) vs. mock-treated human bronchial ALI .
Techniques Used: Generated, RNA Sequencing, Quantitative RT-PCR, Expressing, Infection, Gene Expression, Labeling
Figure Legend Snippet: a , Heatmap showing gene expression log 2 -fold changes (from EdgeR bulk RNA-seq differential gene expression analysis) of selected pro-inflammatory genes and selected ISGs in universal IFNα2 (uIFNα2) or IFNλ1 vs. mock-treated human SI ORG or human Bronchial ALI (n = 3 each). b , Same as for (a) but for IFN-treated bat SI ORG (n = 3), bat alv ORG (n = 3), or bat nasal ORG (n = 3). c , Same as for (a) but for MARV-, MERS-CoV- or SeV-infected bat alv ORG (n = 3 each), SeV-infected bat SI ORG (n = 3), or MARV-infected bat nasal ALI (n = 3). Comparisons used for calculation of edgeR log 2 -fold change are indicated in the legend.
Techniques Used: Gene Expression, RNA Sequencing, Infection
Figure Legend Snippet: a , Scatter plots showing the log 2 -transformed fold changes in gene expression from bulk RNA-seq comparing nasal ORG (left), alv ORG (middle) or SI ORG (right) treated with universal IFNα2 ( x axis) or IFNλ1-like ( y axis) to mock-treated controls after 8 h. Individual ISGs are highlighted. IFNL3 -like ( LOC107521776 ) is highlighted in red. b , RT–qPCR analysis of IFNL3 -like ( LOC107521776 ) in bat SI ORG or alv ORG ; IFNL3 in human SI ORG ) normalized to EEF1A1 (2 −Δ C t ) after treatment with bat IFNλ1-like (bat organoids) or human IFNλ1 (human SI ORG ) for 4 and 8 h. A two-sided Student’s t -test was used to compare IFNL3 -like mRNA levels at 4 or 8 h after treatment to mock-treated controls. c , Scatter plot showing the log 2 -transformed fold changes in gene expression from bulk RNA-seq comparing SI ORG treated with universal IFNα2 ( x axis) or IFNλ3-like (derived from LOC107521776 ) ( y axis) to mock-treated controls after 8 h. Individual ISGs are highlighted in red. d , RT–qPCR analysis of IFNL3 -like ( LOC107521776 ) or MX1 (normalized to EEF1A1 , 2 − Δ C t ) in bat SI ORG engineered with Cas9 and IRF9 targeting (sgIRF9) or control (sgScrambled) RNA, treated with or without bat IFNλ1-like for 8 h. A two-sided Student’s t -test was used to compare IFNL3 -like mRNA levels between sgIRF9 and sgScrambled SI ORG at 8 h after treatment. e , As in d but comparing sgIRF9 and sgScrambled SI ORG after infection with VSV-eGFP at an MOI of 0.05 for 72 h. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Techniques Used: Transformation Assay, Gene Expression, RNA Sequencing, Quantitative RT-PCR, Derivative Assay, Control, Infection
Figure Legend Snippet: a , Experimental workflow showing the administration of universal IFNα2, IFNλ1-like or IFNλ3-like 12 h before, during or 8 h after treatment with VSV infection of bat nasal ORG or SI ORG . Intracellular VSV viral RNA was measured 24 h after infection. b , c , RT–qPCR analysis of intracellular VSV-NP viral RNA in bat SI ORG ( n = 3) ( b ) or nasal ORG ( n = 3) ( c ), normalized to EEF1A1 (2 −Δ C t ) and expressed as a percentage relative to no IFN control. A two-sided Student’s t -test was used to compare VSV viral RNA levels across before, during and after treatment, and no IFN conditions, comparing each IFN treatment to no IFN control. d , Experimental workflow showing bat nasal ORG or SI ORG treated with universal IFNα2 or bat IFNλ1-like for 3 h, followed by washout and incubation in IFN-free medium for 24 h and RNA collection at 0, 3 and 24 h after IFN washout. e , f , RT–qPCR analysis of ISGs (normalized to EEF1A1 ) in bat SI ORG ( n = 3) ( e ) or nasal ORG ( n = 3) ( f ) treated with universal IFNα2 or bat IFNλ1-like at 3 h (left) or 24 h (right) after IFN removal. A two-sided Student’s t -test was used to compare ISG mRNA levels between treatments. g , RT–qPCR analysis of intracellular SINV-eGFP nsP2-P726G nsP1 RNA (normalized to EEF1A1 (2 −Δ C t ) and expressed as fold change relative to the mean of the sgScrambled control) in bat SI ORG engineered with Cas9 and targeted guide RNA (sgIRF9, sgIFNAR2, sgIFNLR1) or control (sgScrambled), infected with SINV-eGFP nsP2-P726G . A two-sided Student’s t -test was used to compare SINV nsP 1 viral RNA levels between treatment groups. nsP1, nonstructural protein 1. h , RT–qPCR analysis of intracellular MARV-L viral RNA (normalized to EEF1A1) in bat SI ORG , nasal ORG or alv ORG ( n = 4) treated with or without IFNs during a 3-day MARV infection. A two-sided Student’s t -test was used to compare MARV viral RNA levels between IFN-treated and untreated controls. i , RT–qPCR analysis of MARV-L viral RNA in bat alv ORG treated with or without 5 µM ruxolitinib during a 3-day infection. A two-sided Student’s t -test was used to compare MARV viral RNA levels between ruxolitinib and dimethylsulfoxide (DMSO) mock-treated alv ORG and MARV -infected alv ORG . * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Techniques Used: Infection, Quantitative RT-PCR, Control, Incubation
Figure Legend Snippet: a , Experimental workflow to assess the temporal induction and maintenance of ISG expression. Bat Nasal ORG or SI ORG are treated with universal IFNα2 (uIFNα2) or bat IFNλ1-like for 3 hours, followed by washout and incubation in IFN-free medium for 24 hours. b , Heatmaps showing RT-qPCR analysis of selected ISGs in bat SI ORG (n = 3), with expression values calculated using the 2 - ΔΔCT method: first normalized to EEF1A1 (2 –ΔCT ), then to baseline levels at −3 h (before treatment). Timepoints shown include before IFN treatment (−3 h), immediately after treatment (0 h), and various hours post-interferon removal (+6h, +24h). Each heatmap value represents the average normalized ISG expression across three biological replicates. Left, uIFNα2. Right, IFNλ1-like treatment. c , same as in (b) but for bat nasal ORG . d , RT-qPCR analysis of IFIT1 (normalized to EEF1A1 (2 –ΔCT ), then expressed as a percentage relative to the average sgScrambled control in bat nasal ORG engineered with Cas9 and a targeted guide RNA (sgIRF9, sgIFNAR2 or sgIFNLR1) or control guide RNA (sgScrambled) (n = 3 each), treated or not for 8 h with uIFNα2 or bat IFNλ1-like.
Techniques Used: Expressing, Incubation, Quantitative RT-PCR, Control

